US 10,951,890

Application 16/045,975 · Granted Mar 16, 2021

Low-latency, peer-to-peer streaming video

Estimated expiration

August 27, 2038

11y 282d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
May 16, 2018
+ 20 years
May 16, 2038
PTA +103d
Aug 27, 2038
No TD
—
Final
Aug 27, 2038

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
July 26, 2018
Earliest effective filing
May 16, 2018
Issue date
March 16, 2021
PTA
+103 days
Base expiry (before PTA)
May 16, 2038

May 16, 2018 + 20 years = May 16, 2038 + 103 PTA days = August 27, 2038

  • Continuation of application 15/981,217, filed May 16, 2018
  • PRO62/506,821 — Provisional — not used for base term
  • PRO62/506,821 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 16/045,975 · US 10,951,890

PatentReply compiles the prosecution history behind US 10,951,890: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US10951890

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.